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Stroke is a leading cause of morbidity and mortality worldwide. Atrial fibrillation (AF) is an independent risk factor for stroke, increasing the risk
five-fold. Strokes in patients with AF are more likely than other embolic strokes to be fatal or cause severe disability and are associated with higher
healthcare costs, but they are also preventable. Current guidelines recommend that all patients with AF who are at risk of stroke should receive
anticoagulation. However, despite this guidance, registry data indicate that anticoagulation is still widely underused. With a focus on the 2012
update of the European Society of Cardiology (ESC) guidelines for the management of AF, the Action for Stroke Prevention alliance writing
group have identified key reasons for the suboptimal implementation of the guidelines at a global, regional, and local level, with an emphasis
on access restrictions to guideline-recommended therapies. Following identification of these barriers, the group has developed an expert con-
sensus on strategies to augment the implementation of current guidelines, including practical, educational, and access-related measures. The po-
tential impact of healthcare quality measures for stroke prevention on guideline implementation is also explored. By providing practical guidance
on how to improve implementation of the ESC guidelines, or region-specific modifications of these guidelines, the aim is to reduce the potentially
devastating impact that stroke can have on patients, their families and their carers.
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Introduction
In 2012, stroke was estimated to have contributed to the deaths of
6.7 million people worldwide, accounting for nearly 12% of all
deaths.1 Stroke causes permanent disability in nearly 5 million
people each year.2 Atrial fibrillation (AF) is a significant independent
risk factor for stroke, associated with an approximately five-fold
excess in risk, but is much less well recognized than, for example,
hypertension, for which the excess stroke risk is three-fold.3 In add-
ition, unlike most other cardiovascular risk factors for stroke, the
pivotal Framingham Study found an increase in attributable risk due
to AF from 1.5% in individuals aged 50–59 years to 23.5% for those
aged 80–89 years.3 Atrial fibrillation is the most common sustained
cardiac arrhythmia and represents a global problem (Figure 1).4–8
Patients with AF are five times more likely to have a stroke than the
general population.3 Atrial fibrillation-related strokes are almost
twice as likely to be fatal and, in survivors, cause severe disability, in-
creasethe lengthofhospital stayanddecrease the likelihoodofpatients
returning to their own home, compared with non-AF-related
strokes.9,10 Atrial fibrillation-related strokes have also been associated
with significantly higher mean direct costs per patient than non-AF-
related strokes.11 However, AF-related strokes can be prevented
and their impact minimized by effective management strategies includ-
ing increased detection of AF, adherence to stroke prevention guide-
lines and anticoagulant use in at-risk patients. Left atrial appendage
occlusion may also have a role in patients who are unable to receive
long-term anticoagulant management, but it is not a recommended
alternative to anticoagulation per se.12
* Corresponding author. Tel: +44 20 8725 3414; fax: +44 20 8725 3416. E-mail address: jcamm@sgul.ac.uk
† See appendix for full list of authors.
& The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits
non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Europace (2015) 17, 1007–1017
doi:10.1093/europace/euv068
Guidelines have an important role in optimizing evidence-based
care, improving health outcomes for individuals and populations and
decreasing costs to healthcare systems. Despite the risk of stroke in
patients with AF, and the availability of clear global guidelines on the
prevention of AF-related stroke since 1999, real-world data suggest
that a large proportion of patients [38% of those with a CHADS2
(Congestiveheart failure,Hypertension,Age≥75years,Diabetesmel-
litus, prior Stroke/transient ischaemic attack (doubled)) score of 2 in
the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation
(GARFIELD-AF) Registry] are still not receiving stroke prophylaxis in
line with guideline recommendations.13 With the increased conveni-
ence and improved benefit–risk profile of the non-vitamin K antagon-
istoral anticoagulants (NOACs; rivaroxaban, dabigatran, apixaban, and
edoxaban), this situation may improve.
This consensus document aims to identify barriers to guideline im-
plementation worldwide and to define clear strategies and practice
models to help overcome these barriers, focusing on the European
Society of Cardiology (ESC) guidelines for the management of AF pub-
lished in EP Europace in 2012.12 A Medline search was performed to
identify guidelines for stroke prevention in patients with AF and bar-
riers to guideline implementation, focusing on registry data but includ-
ing individual studieswhere relevant.TheAction for StrokePrevention
alliance writing committee also provided their own country-specific
experiences and, based on the collated information, identified key bar-
riers to guideline implementation and developed consensus strategies
to help overcome these barriers.
Guidelines overview
Afocusedupdateof the2010ESCguidelines for themanagementofAF
was issued in 2012.12 This was partly in response to positive Phase III
clinical trial data with the NOACs dabigatran, rivaroxaban, and
apixaban,14–16 and their subsequent approval for stroke prevention
in at-risk patients with non-valvular AF. The NOACs have shown
equivalentor improvedefficacycomparedwithwarfarin inrandomized
controlledtrials,withareductionintheriskofseverebleedingevents, in
particular intracranial haemorrhage (ICH).14–17 In addition, they all
offer fixed-dose regimens (with some dose reductions mandated in
special populations, such as patients with renal impairment) that elim-
inate the need for the routine coagulation monitoring associated with
vitamin K antagonists (VKAs). Edoxaban is currently the only one of
these NOACs that is not yet widely approved in this indication. The
ESC guidelines now recommend the use of the NOACs in most
patients with a CHA2DS2-VASc [Congestive heart failure/left ventricu-
lar dysfunction, Hypertension, Age ≥75 years (doubled) Diabetes,
Stroke (doubled), Vascular disease, Age 65–74 years, Sex category
(female)] score of ≥1 in preference to VKAs (Figure 2), although in
certain patients, e.g. those with severe renal impairment or underlying
disease on echocardiogram, VKAs remain preferred. Antithrombotic
treatment is not recommended in low-risk patients with a CHA2DS2-
VASc score of 0.12 However, the latter group represented only 3–7%
of patients in two large cohort studies,13,18 indicating that the majority
of patients with AF are candidates for oral anticoagulation.
In large Phase III studies, the currently approved NOACs showed
similar or improved efficacy compared with warfarin for the preven-
tion of primary stroke or systemic embolism.19–21 Several of the
NOACs have also demonstrated benefits in the prevention of second-
ary strokes, with similar efficacy to warfarin, as well as reducing the in-
cidence of ICH.19–21 The risk of a stroke recurrence is 2.5-fold higher
in patients with AF who have already had a stroke or transient ischae-
mic attack.22 These patients may also be at increased risk of falls, have
dementia or have limited access to international normalized ratio
(INR) monitoring because of decreased mobility, making it problemat-
ic to ensure effective VKA therapy.
United States:
2.3 million (2008)
(estimated 5.6–>12 million by 2050)
European Union:
10 million (2011)
Japan:
0.8–2.0 million
(2011)
China:
8 million (2008)
Australia:
0.9 million (2011)
India:
1.2 million* (2011)
Brazil:
4.8 million (2009)
Figure 1 Estimates of the prevalence of AF.4– 8 *Based on data from a single community study.
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In addition to incorporation of the NOACs into the recommenda-
tions, another significant change to the ESC guidelines was a move
away from the use of the CHADS2 score to risk-stratify patients
with AF, in favour of the CHA2DS2-VASc score. This was based on
evidence that the CHA2DS2-VASc score could be used to more
accurately identify truly ‘low-risk’ patients, who would not require
antithrombotic therapy.12
The 2012 guidelines also recommend the use of the HAS-BLED
[Hypertension, Abnormal renal/liver function, Stroke, Bleeding
history or predisposition, Labile INR, Elderly (e.g. age .65 years,
frailty, etc.), Drugs/alcohol use] score to assess bleeding risk, but
highlight that it should focus efforts on improving the modifiable
risk factors for bleeding and should not be used to exclude patients
from oral anticoagulant therapy.12
The simultaneous use of old and new guidelines, or of guidelines
issued by different organizations, at either a global or regional level,
can lead to adegreeof confusion orcontradictory guidance. In addition,
recommendations may differ between guidelines because of variations
inthepopulations forwhichtheyare intended.However, recommenda-
tions for antithrombotic therapy are, for the most part, consistent
between the major guidelines. In 2012, the American College of
Chest Physicians (ACCP) issued guidelines on antithrombotic therapy
for AF, which provide similar recommendations to the ESC guidelines
(based onCHADS2 scoring for risk assessment), including a preference
for NOACsoveradjusted-dose VKAs in at-riskpatients.23 Older guide-
lines, suchas those jointly issuedby theAmericanCollegeofCardiology
(ACC), the American Heart Association (AHA), and the ESC in 2006,
were developed long before the NOACs were available to clinicians
and, in contrast with newer guidelines, recommend acetylsalicylic acid
(ASA) as an alternative to warfarin in patients with one moderate risk
factor for stroke.24 Updated ACC/AHA guidance, issued in 2014,
recommends oral anticoagulation for patients with prior stroke/transi-
ent ischaemic attack or CHA2DS2-VASc score ≥2, whereas patients
with a score of 1 may be given oral anticoagulation, ASA, or no antith-
rombotic therapy.25 In 2013, the European Heart Rhythm Association
published a practical guide on the use of NOACs in patients with non-
valvular AF26 based on the 2012 ESC recommendations.
Country-specific guidelines, such as those from the National Insti-
tute for Health and Care Excellence (NICE) in the UK, recommend
apixaban, dabigatran, and rivaroxaban as options for the prevention
of stroke or systemic embolism in patients with AF.27 A focused
update of the Canadian Cardiovascular Society (CCS) Atrial Fibrilla-
tion Guidelines, published in 2012, recommends NOACs over other
oral anticoagulants in eligible patients.28 In the Asia-Pacific region,
several countries have country-specific guidelines for the manage-
ment of patients with AF but not all yet incorporate recommenda-
tions for the use of NOACs. However, the 2014 Japanese
guidelines largely support the ESC 2012 guidelines, as does a consen-
sus statement issued in 2013 by the Asia Pacific Heart Rhythm
Society on antithrombotic therapy in patients with non-valvular
AF.29 Information provided by other organizations, such as the
National Stroke Association in the UK or the Canadian Agency for
Drugs and Technologies in Health, who issue therapeutic reviews,
may also influence clinical practice at a national level.
Guideline implementation
and barriers to implementation
Benefits of compliance with guidelines
Acriticismof guidelines is that theysometimes relyonevidence that is
relatively weak and/or studies that have been conducted with
Valvular AFa
<65 years and lone AF (including females)
Oral anticoagulant therapy
NOAC VKANo antithrombotic
therapy
No
No (i.e. non-valvular AF)
0 1 ≥2
Yes
Yes
Atrial fibrillation
Assess bleeding risk
(HAS-BLED score)
Consider patient values
and preferences
Assess risk of stroke
(CHA2DS2-VASc score)
Figure 2 European Society of Cardiology (ESC) guideline recom-
mendations for thepreventionof stroke inpatientswithAF.12 Antipla-
telet therapy with ASA plus clopidogrel, or—less effectively—ASA
only, should be considered in patients who refuse any oral anticoagu-
lant or cannot tolerate anticoagulants for reasons unrelated to bleed-
ing. If therearecontraindications tooral anticoagulationorantiplatelet
therapy, left atrial appendage occlusion, closure, or excision may be
considered. CHA2DS2-VASc score: turquoise, 0; yellow, 1; red, ≥2.
Line: solid, best option; dashed, alternative option. aIncludes rheumat-
ic valvular disease and prosthetic valves. AF, atrial fibrillation; ASA,
acetylsalicylic acid; CHA2DS2-VASc, ESC-recommended stroke risk
score[Congestiveheart failure/leftventriculardysfunction,Hyperten-
sion, Age ≥75 years (doubled) Diabetes, Stroke (doubled), Vascular
disease, Age 65–74 years, Sex category (female)]; HAS-BLED,
[ESC-recommended bleeding risk score, defined as Hypertension,
Abnormal renal/liver function, Stroke, Bleeding history or predispos-
ition, Labile INR, Elderly (e.g. age .65 years, frailty, etc.), Drugs/
alcohol use]; NOAC, non-vitamin K antagonist oral anticoagulant;
VKA, vitamin K antagonist. From Camm et al. 2012 focused update
of the ESC Guidelines for the management of atrial fibrillation.
European Heart Journal Nov 2012, 33(21) 2719–2747. Reproduced
with permission of Oxford University Press (UK) & European
Society of Cardiology, www.escardio.org/guidelines
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inconsistent methodologies. However, the evidence for the use of
NOACs in patients with non-valvular AF comes from very large, mul-
ticentre, randomized controlled Phase III studies,14– 16 and the
primary recommendations made by the ESC in 2012 on anticoagula-
tion in patients with AF generally carried a high level (A or B) of evi-
dence.12 Nevertheless, prospective clinical data for the NOACs are
lacking in some specific areas; e.g. a prospective randomized study of
rivaroxaban for patients with AF undergoing cardioversion has been
published recently,30 but a similar trial for apixaban (NCT02100228)
is only just getting underway, and there is no such prospective study
planned for dabigatran. Studies to address other data gaps with the
NOACs are ongoing.
Published studies support the benefits of compliance with guideline
recommendations for anticoagulation in patients with AF. A cross-
sectional study of patients admitted to the University of Maastricht
Medical Centre between 2003 and 2006 found that 51% of those
with known AF who were eligible for oral anticoagulation did not
receive it, and that improved adherence to guidelines could potentially
have prevented 22% of subsequent ischaemic strokes.31 More recent-
ly, a real-world cohort-based study of almost 9000 patients recruited
over 10 years found low annual rates of stroke or thromboembolism
(0.64%), major bleeding (1.12%), and death (1.08%) among untreated
patients classified as low risk according to the ESC 2012 guidelines (i.e.
CHA2DS2-VASc score 0).
18 These data support the ESC recommen-
dation that these patients should not receive antithrombotic therapy.
Furthermore, simulations of patient outcomes from the RE-LY
database using ESC-recommended dabigatran treatment protocols
foundasignificantnetclinicalbenefitcomparedwithwarfarin, support-
ing the ESC recommendations.32
Compliance with guidelines in practice
Registry data offer valuable insights into patterns of drug use and can
provide a means of tracking uptake of guideline recommendations.
For example, global data from the GARFIELD-AF Registry, collected
between 2009 and 2011, indicated that 27% of all patients with AF
were still receiving ASAtherapy, compared with60% whoreceived
oral anticoagulation (Table 1).13 However, observational data
from the European PREFER AF (PREvention oF thromboembolic
events—European Registry in Atrial Fibrillation) registry collected
between 2012 and 2013 suggest that the introduction of the 2010
ESC guidelines was associated with a move away from the use of
ASA to oral anticoagulation.40 Other European registry data show
variation in oral anticoagulation use depending on when the data
were collected and from which country or countries (Table 1).35–41
Outside of Europe, US registry data indicate a low use of oral anticoa-
gulation across all stroke risk categories.43 Data from the REACH
registry (REduction of Atherothrombosis for Continued Health)
demonstrated the lower use of oral anticoagulation in patients with
AF recruited from Asia (excluding Japan) compared with those
recruited from Japan and non-Asian regions.45 These differences high-
light thatoralanticoagulantuse is notyetconsistentat a global, country,
or regional level and may be influenced by factors such as the specialty
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Table 1 Atrial fibrillation registries and surveys
Registry or study Guidelines Patients with
AF, n
Country/region Data collection, year OAC use (%)
GARFIELD-AF13 Multiple 10 614 Global 2009–2011 60
RE-LY AF33 Multiple 15 400 Global 2008–2011 30
GLORIA-AF34 Multiple 56 000 Global 2011 onwards Awaiting data
Euro Heart Survey on AF35 ACC/AHA/ESC 2001 and
ACCP 2004
5333 Europe 2003–2004 64
AFNET36 ACC/AHA/ESC 2001 9582 Germany 2004–2006 71
ATRIUM37 ACC/AHA/ESC 2001 and
ACCP 2008
3667 Germany 2009 83
Prospective non-interventional study38 Not specified 2753 Germany 2010 64–73a
ISAF39 Not specified 6036 Italy 2011 46
PREFER AF42 ESC 2010 7243 Europe 2012–2013 82
Retrospective, cohort study43 ACC/AHA/ESC 2006 and
ACCP 2008
171 393 USA 2003–2007 43
ORBIT-AF44 ACC/AHA/ESC 2006 and
ACCP 2008
10 098 USA 2010–2011 76
REACH45 Not specified 300 Asia (ex. Japan) 2006–2011 36
REACH45 Not specified 350 Japan 2006–2011 54
REACH45 Not specified 6000 Global (ex. Asia) 2006–2011 55
ACC, American College of Cardiology; ACCP, American College of Chest Physicians; AF, atrial fibrillation; AFNET, Central Registry of the German Competence NETwork on Atrial
Fibrillation; AHA, American Heart Association; ATRIUM, Outpatient Registry Upon Morbidity of Atrial Fibrillation; CHADS2, Congestive heart failure, Hypertension, Age≥75 years,
Diabetes mellitus, prior Stroke/transient ischaemic attack (doubled); ESC, European Society of Cardiology; GARFIELD-AF, Global Anticoagulant Registry in the FIELD; GLORIA-AF,
Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation; ISAF, Italian Network of Atrial Fibrillation Management survey; OAC, oral
anticoagulant; ORBIT-AF, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation; PREFER AF, PREvention oF thromboembolic events—European Registry in Atrial
Fibrillation; REACH, REduction of Atherothrombosis for Continued Health; RE-LY AF, Randomized Evaluation of Long-term anticoagulant TherapY.
aCHADS2 score ≥2 (includes low molecular weight heparin).
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of the physicians enrolling patients into the registries and the degree of
awareness of updated guidelines.
Patient and physician-related barriers
Registries can also provide useful information on the reasons for
non-adherence to guidelines and identify barriers to their adop-
tion. GARFIELD-AF highlighted that nearly half of patients with a
CHADS2 score ≥2 were not receiving VKA therapy because of
physician choice, specifically because of concerns over bleeding
risk, patient compliance, uncertainty regarding guideline recom-
mendations, fall risk or low risk of stroke.13 Patient factors, such
as alcohol misuse, medication refusal, unsuitable co-medication
use, or previous bleeding events, were the reasons for not initiat-
ing VKA therapy in ,16% of cases.13 Similar reasons were given
for warfarin discontinuation in the Outcomes Registry for Better
Informed Treatment of Atrial Fibrillation (ORBIT-AF).46 Similarly,
in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Pre-
vention of Vascular Events (ACTIVE) A trial, which enrolled
patients who were considered unsuitable for VKA therapy, the
primary reason for enrolment in the trial (accounting for 50%
of patients) was physician judgement that a VKA was inappropri-
ate. Patient preference accounted for 26% of patients enrolled,
and specific risk of bleeding for 23% of patients.47 In the Apix-
aban vs. Acetylsalicylic Acid to Prevent Strokes in Atrial Fibrillation
Patients Who Have Failed or Are Unsuitable for Vitamin K Antag-
onist Treatment (AVERROES) study, the most frequent reasons
for not prescribing VKAs were physician judgement that INR mon-
itoring could not be achieved at the requisite frequency (43%) and
patient preference (37%).48
The Stroke and Atrial Fibrillation Ensemble (SAFE) II study found
that having a younger general practitioner and being followed up by
a cardiologist were independently associated with the prescription
of oral anticoagulants.49 The presence of potential contraindications,
lack of an indication, low compliance, and fear of bleeding were
reasons given for non-prescription.49 These findings highlight that
the lack of physician awareness about oral anticoagulation and how
to manage complications is a key barrier to adoption of guideline-
recommended therapies. A general survey of Dutch general practi-
tioners also identified environmental factors such as organizational
constraints, lack of time, and lack of resources as prominent barriers
to guideline adherence.50 Furthermore, uptake of NOACs may be
limited by a physician preference for close INR monitoring, particu-
larly in elderly or frail patients.
Another barrier to the adoption of guidelines arises when they are
not considered applicable at a country level, possibly because of re-
gional heterogeneity in patient baseline characteristics (e.g. a high
proportion of patients not meeting the criteria for recommended
treatments or aperception that the studies underpinning recommen-
dations are based on non-representative populations), differences in
current standards of care or cultural perceptions of risk vs. benefit of
the intervention. Forexample, in some Asian countries, such as Japan,
the recommended target INR in patients with AF ≥70 years of age is
lower (1.6–2.6) than the recommended target of 2.0–3.0, which is
used more widely.51 Similarly, a lower 15 mg once-daily dose of riv-
aroxaban (or 10 mg once-daily in patients with creatinine clearance
30–49 mL/min) was specifically tested in Japanese patients.52
Access to guideline-recommended
therapies
In some countries, prescribing of the NOACs is restricted at a nation-
al, regional, or local level. For example, the National Health Service
for Scotland limits the prescription of rivaroxaban to patients who
appear compliant with coumarin therapy and yet still have poor
INR control, as well as to those who are allergic to or are unable to
tolerate coumarins.53 In the UK, the Department of Health follows
the NICE guidelines rather than the ESC guidelines. However, even
though the NOACs are recommended as a therapeutic option by
NICE, many clinical commissioning groups or regional prescribing
groups in the UK interpret this ‘option’ as second line, with warfarin
compulsory as first-line therapy.54,55 In the UK and Ireland, patients
who are closer to the hospital and can attend clinics regularly for co-
agulation monitoring and dose adjustments are also more likely to
receive VKAs than those who live further away. In Eastern European
countries (e.g. Hungary), the National Health Service limits the pre-
scription of NOACs to patients who have had a previous stroke or
patients with poor INR control on coumarin therapy.56 This restric-
tion is in place because the first-line use of the NOACs is considered
financially prohibitive.
Restricted access can also be a result of administrative barriers. For
example, in Italy and Hungary, a limited number of specialists are
allowed to prescribe the NOACs; to finalize the prescription,
these specialists are required to fill out an electronic case
report form, contributing to a compulsory national survey (www.
agenziafarmaco.gov.it). This is a time-consuming process and, as
such, the national Regulatory Authorities have indirectly discouraged
routine implementation of the ESC guidelines for antithrombotic
treatment. The bureaucratic situation in Italy is mirrored in other
countries: in Ireland and some parts of England, justification forms
must be completed to allow physicians to prescribe the NOACs
and, in Spain, patients must have an INR that is recorded to be out
of range three times in a row before a patient can be prescribed
any of these drugs, and this may take weeks.
Access issues can also arise when updates to guidelines are
delayed. For example, the European Stroke Organisation (ESO)
has not updated its guidelines on secondary stroke prevention
since 2008,57 and so the NOACs are not included. This influences
the daily practice of stroke specialists: in some Eastern European
countries, for instance, physicians face financial penalties or even
imprisonment if they are not compliant with the guidelines
recommended for their specialty, even if the guidelines are out-
dated and do not reflect the latest clinical advances in the field.
In cases such as these, pre-existing guidelines, though relevant
when they were published, are themselves a barrier to adopting
new approaches or therapies. An update to the ESO guidelines
is anticipated.
Even if guidelines are up to date, it does not necessarily guarantee
access to recommended therapies. For example, a group of Spanish
medical experts developed a consensus document in line with the
ESC guidelines that was approved by the Spanish Ministry of Health
for national use.58 However, access to NOACs is still often restricted
by local authorities because warfarin is considered to be as effective
as the NOACs and is a low-cost drug, albeit with high monitoring
costs. Therefore, the newer drugs are often limited to patients
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who are unstable on warfarin or who have had an ischaemic stroke
and are at high risk of ICH.
Financial barriers to
guideline-recommended therapies
One of the major reasons for restricted access to new guideline-
recommended therapies is perceived cost. Restrictions tend to be
made based on a consideration of short-term budget impact, such
as the lower acquisition costs of VKAs compared with the NOACs,
rather than the potential longer term economic impact of events
that might have been prevented. Non-vitamin K antagonist oral antic-
oagulants do not require routine coagulation monitoring, which, in
one US study, was shown to cost between $291 and $943 annually
per patient.59 The National Institute for Health and Care Excellence
has estimated the annual cost of INR monitoring, including transport
costs, at£656 in thefirst yearand£540 thereafter.60 Longer termcost
savings relate to the direct costs of managing the consequences of
anticoagulation, which are summarized in Table 2. For example, con-
sidering that NOACs reduce the risk of ICH by at least half compared
with warfarin, their use could contribute substantially to long-term
cost savings (Table 3). A study in Denmark published in 1999 esti-
mated that, after ICH, the mean total costof healthcareand social ser-
vices during the first year was 123 200 DKK or US$22 000.63 More
recently, a study in the USA analysing medicine and pharmacy
claims for patients with AF estimated the mean unadjusted
all-cause health costs in the year after a warfarin claim to be $41
903 for patients with at least one ICH.64 Despite this, it is often diffi-
cult in practical terms to implement a scheme in which a more expen-
sive therapy is paid for from one budget (in this case, drug costs) to
provide cost savings that relate to a separate budget (blood tests
and monitoring).
The lack of monitoring of the NOACs may also represent a finan-
cial barrier to their implementation. In some countries, primary care
practices and anticoagulation clinics receive a financial incentive for
providing VKA monitoring services, which could be considered
under threatwith the introduction of the NOACs. However, with ap-
propriate training of personnel, these facilities could be repurposed
to take on a role in the initiation and management of the NOACs
and management of co-morbidities and to provide valuable guidance
and reassurance to patients about their anticoagulation care. Indeed,
overall risk factor control, not limited to the use of NOACs, is the
most important therapeutic intervention for patients with AF.
Financial barriers to appropriate VKA management specific to in-
dividual countries or regions also exist. In many Eastern and Central
European countries, both INR monitoring and travel costs (for blood
sampling) are covered by the healthcare system. However, blood
sampling takes place in large centralized laboratories that are often
a long distance from where the patient lives, meaning that substantial
work time is lost through travelling to and from appointments; this
can also have a negative impact on patient compliance.
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Table 2 Overview of event costs. Adapted from Kleintjens et al.61
Eventa Acute (per event) (E) Rehabilitation
(per event)b (E)
Long-term follow-up
(per 3 months) (E)
Minor stroke 5946 3204 244
Major stroke 12 247 17 734 2216
Systemic embolism 5124 Not reported Not reported
Clinically relevant non-major extracranial bleeding event 23 Not reported Not reported
Major extracranial bleeding event 3510 Not reported Not reported
Intracranial bleeding eventc 7699 17 734 2216
Myocardial infarction 7891 Not reported Not reported
aThe range of event costs tested in sensitivity analyses was+25% of the mean.
bBased on unpublished results (K. Putman, personal communication).
cBased on market share and prices of locally available brands.
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Table 3 Absolute percentage annual risk of ICH stratified by stroke risk in patients with non-valvular AF receiving oral
anticoagulation therapy for stroke prevention. Adapted from Rognoni et al.62
Intracranial bleeding, absolute annual risk (%)
CHADS2 ≤ 1 CHADS2 5 2 CHADS2 ≥ 3
Warfarin 0.48 0.65 1.01
Rivaroxaban (20 mg od) Not investigated 0.44 0.68
Apixaban (5 mg bid) 0.2 0.27 0.42
Dabigatran (150 mg bid) 0.2 0.26 0.52
bid, twice daily; CHADS2, Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke/transient ischaemic attack (doubled); od, once daily; ICH,
intracranial haemorrhage.
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In Brazil and many South East Asian countries, only 30% of patients
have private health insurance and, therefore, have access to the
newer therapies for stroke prevention inpatientswith AF. In contrast,
patients treated in the public sector typically continue to receivewar-
farin or another VKA because these drug costs are supported by the
healthcare system. In Brazil and Mexico, the local authorities can sub-
sidize more expensive medications, but it takes time to get new ther-
apies included on these lists and, because it is not a national
responsibility, differences in access exist between local authorities.
In cost-effectiveness analyses, the NOACs have been shown to be
cost-effective compared with warfarin.61,65–74 Robust and well-
designed cost-effectiveness analyses can be important when arguing
the case for consideration of new therapeutic options with policy
makers. However, these analyses are not without limitations. Their
general applicability can be limited because of differences in healthcare
systems between countries. Furthermore, cost-effectiveness analyses
may be inadequate because they do not take into consideration all
factors, particularly indirect costs including loss of work for patients
orcarersdueto INRclinic visits andassociated travelcosts.75 Addition-
ally, even demonstrating the cost-effectiveness of a drug within the
parameters defined in the analysis may not provide a comparison of
cost-effectiveness relative to other established treatments.
In addition to their cost-effectiveness, the relative effectiveness
and safety of the NOACs compared with the VKAs is an important
benefit. The convenience to patients in terms of lack of monitoring
and dietary restrictions, which is likely to improve persistence and ad-
herence and therefore clinical outcomes, should also not be under-
estimated.
Best practice in European Society
of Cardiology guideline implementation
Registry data highlight that it can take several years for guideline
recommendations to be implemented in clinical practice, and
even then, recommendations may not be applied properly or con-
sistently. It is also clear that there is wide variation between coun-
tries regarding which recommendations are implemented and how
this is achieved. When the writing committee rated the import-
ance of certain factors for guideline implementation, variation
between countries did exist, but factors such as AF screening,
diagnosis, and stroke risk assessment were rated of high import-
ance across the group.
The barriers to guideline implementation that the group identified
(summarized in Table 4) fall into three main categories: practical, edu-
cational, and access related. Practical issues relate primarily not only
to optimal diagnosis and risk stratification of patients with AF but also
to the applicability of the ESC guidelines to non-European popula-
tions. Lack of awareness of the ESC guidelines and delays in
updates to local or national guidelines are the key educational bar-
riers that exist, despite the efforts of the ESC to promote its guide-
lines through various methods, including ‘train the teacher’
programmes, ESC guideline implementation toolkits, and mobile
pocket guidelines. Another educational barrier stems from the
variety of information available about the NOACs, which can lead
to confusion over their specific properties and use protocols.
Access-related issues are primarily due to cost and also include
other factors that have been discussed above.
In light of these barriers, the Action for Stroke Prevention alliance
writing committee recommends several best-practice strategies
(summarized in Table 5) to improve adherence to the ESC guidelines
(or their region-specific modification) and access to guideline-
recommended therapies.
Measuring healthcare quality for stroke
prevention: potential role in guideline
implementation
Registries provide information on whether guidelines have been
implemented. However, could healthcare quality measures be used
to drive implementation of, and adherence to, guidelines as they
are issued? Unfortunately, data on the use of healthcare quality mea-
sures to improve stroke prevention in patients with AF are generally
limited, although national audit data are available in some countries,
highlighting gaps in care for stroke prevention.76,77
In the USA, there are several initiatives aimed at assessing the
quality of stroke care, including the Stroke Practice Improvement
Network, The Paul Coverdell National Acute Stroke Registry,
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Table 4 Barriers to implementation of ESC 2012
guidelines
Barrier
Practical
† Under-diagnosisofAFbecauseof lackof access todiagnostic tools for
AF (e.g. Holter monitoring)
† Not screening using the most efficient technique, e.g. loop
monitoring for paroxysmal AF
† Underestimation of thromboembolic risk
† Applicability of ESC guidelines to non-European populations
Educational
† Lack of widespread awareness of ESC 2012 Guidelines (coupled with
use of other/pre-existing guidelines)
† Delay in updates of local guidelines to reflect major environmental
changes for practice
† Fear of major bleeding/lack of validated scores to evaluate bleeding
risk (HAS-BLED was developed based on VKA studies)
† Lack of technical expertise
† Development and availability of multiple NOACs in a relatively short
timeframe has led to confusion about protocols for use and the
specific properties of each drug
– Exacerbated by manufacturers providing different information
about the drugs in the prescribing information vs. the summary of
product characteristics and using different marketing approaches
– Influenced by media reports, e.g. reports of severe bleeding when
dabigatran was first introduced
Access
† Budget restrictions and/or reimbursement issues with NOACs
† Limitations/restrictions on patients considered eligible for NOACs
that are inconsistent with broader guideline recommendations
† Limitations of prescriber eligibility
† Administrative hurdles associated with prescription of NOACs (e.g.
completion of paperwork and justification of the clinical decision)
AF, atrial fibrillation; HAS-BLED, Hypertension, Abnormal liver/renal function,
Stroke history, Bleeding predisposition, Labile INR, Elderly (age .65 years), Drug/
alcohol use; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K
antagonist; INR, international normalized ratio.
Non-VKA oral anticoagulants: barriers and strategies 1013
and the ‘Get with the Guidelines’ programme. Likewise, in Australia,
the national prescribing service MedicineWise is a programme that
aims to improve cardiovascular management in primary care.
However, although the use of healthcare quality measures has
shown improvements in care and adherence to guidelines in
some cases, methods for implementing these improvements have
varied and the results have not been consistent.78– 80 In Japan, the
Japanese Stroke Databank is a patient oriented, academically con-
trolled database aimed at establishing rigorous evidence for the
quality improvement of stroke care (http://cvddb.med.shimane-u.
ac.jp). Physicians register data on their own academic incentive
and the databank is endorsed by the representative of stroke
patients, providing a successful collaboration between patients
and physicians to overcome stroke. In the UK, the Quality and Out-
comes Framework incentivizes providers for the provision of high-
quality care, against explicit clinical indicators and defined targets,
and helps to standardize improvements in the delivery of primary
medical services. This system is currently being used to improve
records of patients with AF and their ongoing management and
could be applied to improving the use of NOACs for stroke preven-
tion in patients with AF.
Until validated and standardized healthcare quality measures for
stroke prevention in patients with AF are developed, the role of
such measures in driving ESC guideline implementation is limited.
However, measures developed at a local or hospital level could be
of benefit and warrant further investigation.
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Table 5 Best-practice strategies for implementation of the ESC 2012 guidelines and rationale for such strategies
Strategy Rationale
Practical
Develop hospital and department protocols and checklists based on
national/local guidelines and implement quality indicators
Provides clinical practical guidance for day-to-day management of
patients with AF and allows measurement of guideline adherence
Regular multidisciplinary team meetings and local quality audits Allows assessment of individual patients and can act as an internal check
to ensure they are being managed in line with guideline
recommendations
Enhances peer-to-peer learning experience
Plan follow-up visits and laboratory check-ups Ensures patients are compliant with guideline-recommended therapy
and reduces the risk of complications
Provide clear practical guidance on the use of NOACs Provides reassurance for physicians not experienced in the use of these
drugs
Implement CHA2DS2-VASc and bleeding risk checklists before prescribing
NOACs and at every follow-up visit
Ensures identificationof patients suitable forantithrombotic therapyand
those at increased risk of bleeding
Implement compliance checks, e.g. specific questions, pill ‘counting’, diary
completion, SMS messages or alarm calls to take tablets
Ensures patients are compliant with guideline-recommended therapy,
improves adherence and reduces the risk of complications
Educational
Regularly disseminate ESC/national and local guideline information and updates Raises awareness of guidelines
Develop timely country-specific/local guidelines based on the ESC
recommendations
Allows recognition of country-specific requirements, such as access, so
that guidelines are compatible with local conditions
Re-train/educate nurses currently involved in anticoagulation/warfarin clinics
to take on a more general role in initiation and management of NOACs
Can provide an established point of contact through which patients can
receive advice on anticoagulation with the NOACs
Develop simple algorithms for specific populations of patients with AF, as per
Figure 2 (e.g. post-ischaemic stroke, post-haemorrhagic stroke, geriatric
patients)
Provides guidanceon whenand how to startNOACsand for how long in
these patients
Inform physicians on how to educate patients on the importance of adherence
to therapy
Limits the likelihood of non-adherence to guideline-recommended
protocols
Access
Approach the responsible person within your healthcare system to:
Highlight to key target groups (e.g. budget holders, policy makers, formulary
gate keepers, the media, patient groups) the potential impact of not
providing access to guideline-recommended therapies, from both financial
and clinical perspectives
Raises awareness that AF is a significant risk factor for stroke and that
AF-related stroke is preventable
Perform country-specific cost-effectiveness analyses of the NOACs
Educate payers/budget holders about better utilization of anticoagulants,
including NOACs, highlighting potential long-term cost benefits
Provides payers/budget holders with more robust evidence to consider
the use of the NOACs as first-line therapy
–
Inform politicians, patient groups and the media about differences in access
to AF stroke prevention treatment within regions or countries
Lobby parliamentary and healthcare bodies for equality of access
to guideline-recommended therapies globally or across regions
Puts pressure on policy makers to provide equality of care for stroke
prevention in patients with AF with regards to medication
AF, atrial fibrillation; CHA2DS2-VASc, Congestiveheart failure/left ventricular dysfunction, Hypertension, Age≥75years (doubled), Diabetes, Stroke (doubled), Vascular disease, Age
65–74 years, Sex category (female); NOAC, non-vitamin K antagonist oral anticoagulant; SMS, short message service; ESC, European Society of Cardiology.
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Limitations of these
recommendations
It should be noted that, although the majority of the evidence cited in
this document comes from published clinical studies or real-world
investigations, some of the country-specific information, and the bar-
riers identified as a result, are based on personal evidence provided
by writing committee members. The recommendations provided re-
present the opinion of the group, and would require practical imple-
mentation to test their robustness and applicability to different
healthcare scenarios.Asnotedabove, the lackof certain standardized
structures may prevent some recommendations from being imple-
mented in practice at this time.
Conclusions
Atrial fibrillation-related stroke is potentially preventable and,
through better implementation of the 2012 ESC guidelines, its
impact on patients, their families, and carers, and healthcare
systems can be reduced. However, this cannot be achieved without
increased detection of patients with AF and the increased use of
anticoagulation in those assessed to be at moderate or high stroke
risk, using either well-controlled warfarin or, preferably, NOACs.
Providing patients with a choice of therapy and allowing physicians
to prescribe the most appropriate anticoagulant for their patients
will only be possible if there is access to all guideline-recommended
therapies. In outlining practical measures that physicians and medical
health societies working in this field can instigate to improve guideline
implementation, we believe that substantial benefits, in terms of
improved patient outcomes and reduced healthcare burden, can
be achieved.
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